HBio Q1 FY23 rev. down 26% YoY, adj. EBITDA margin at 44%.

• HBio reports Q4 revenue of $22.2mln, up 28% YoY. • Digital data segment revenue increases 49% YoY. • HBio's gross margin improves to 83.5%. • Adjusted EBITDA increases to $4.3mln from $0.2mln YoY. • HBio's cash and cash equivalents increase to $22.5mln from $18.8mln YoY.